Lupin Receives EIR from US FDA for its Goa Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its facility in Goa, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from November 10 to November 21, 2025.

Nilesh Gupta, Managing Director, Lupin, stated, "We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide."

Shares of Lupin Limited was last trading in BSE at Rs. 2323.20 as compared to the previous close of Rs. 2292.45. The total number of shares traded during the day was 40819 in over 3043 trades.

The stock hit an intraday high of Rs. 2331.20 and intraday low of 2289.35. The net turnover during the day was Rs. 94524998.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals EIR USFDA GoaFacility